Navigation Links
A 'Must Read' for Breast Cancer Patients
Date:12/18/2007

SAN JOSE, Calif., Dec. 18 /PRNewswire/ -- Patent 7,309,486 issued on 12/18/07 to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California discloses a better way of using Genentech's drug Herceptin(R) against breast cancer. The patent discloses that today's practice of concurrent administration of Herceptin(R) with conventional phase specific chemotherapy results in antagonistic action between the two classes of drugs. In later stage cancers, these protocols only increase median survival by several months.

Patent 7,309,486 discloses novel protocols that allow the two classes of chemotherapeutics to function synergistically. The protocols are designed to provide a way of holding the cancer in check indefinitely.

All proliferating cells progress through 4 distinct phases termed G1, S, G2, and M. "S-Phase cytotoxics, such as Pfizer's Camptosar(R) or Eli Lilly's Gemzar(R), are capable of killing virtually all cells that are in the S-Phase, however, in the best case, only around one third of cancer cells are typically in the S-Phase during chemotherapy," explains Mark Zamoyski, the inventor. "The patented protocols boost the number of cells in the S-Phase by exploiting the cancer's unique mutation profile to establish a "road block" to aggregate a large number of cancer cells at a point prior to the S-Phase, the road block is then removed to allow the wave of cancer cells to enter the S-Phase during the administration time of the S-Phase cytotoxic chemotherapy, and then the road block is reestablished to start aggregating surviving cancer cells for the next administration of S-Phase cytotoxic chemotherapy."

The abstract contained in the patent has been incorrectly truncated and a correct synopsis of the patent is available at http://www.nexgen.biz under Cell Cycle Synchronous Chemotherapy.


'/>"/>
SOURCE NexGen Biomedical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Middle East Pharma Manufacturing/Biotech is Ready to Boom
2. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
3. Significant Progress Made in Nations Preparedness to Respond to Public Health Emergencies; But Gaps in Critical Areas Threaten Overall Readiness
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
7. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
10. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
11. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... -- Research and Markets has announced the ...  report to their offering.  , ,     (Logo: ... forecast the global multimodal biometrics market to grow ... 2016-2020.  Multimodal biometrics is being implemented ... healthcare, BFSI, transportation, automotive, and government for controlling ...
Breaking Biology News(10 mins):